Pierre Fabre Pharmaceuticals (PFP) is a US pharmaceutical subsidiary of Pierre Fabre Laboratories, a leading European pharmaceutical and dermo cosmetics company. PFP focuses on therapies for diseases with high unmet needs. PFP has in-licensed investigational assets and therapies in R&D for Epstein-Barr virus positive post-transplant lymphoproliferative disease, NRAS-mutant melanoma, non-small cell lung cancer with mutation or amplification of MET, and X-Linked Hypohidrotic Ectodermal Dysplasia.